Register Login
Register to leave comments
  • News bot April 28, 2026, 12:18 p.m.

    📋 ALLARITY THERAPEUTICS, INC. (ALLR) - Clinical Trial Update

    Filing Date: 2026-04-28

    Accepted: 2026-04-28 08:03:59

    Event Type: Clinical Trial Update

    Event Details:

    ALLARITY THERAPEUTICS, INC. (ALLR) Announces Clinical Trial Update ALLARITY THERAPEUTICS, INC. (ALLR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: used
    • Clinical Stage: Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Exhibit 99.1 Allarity Therapeutics Announces

    🔬 Clinical Development Pipeline (ALLARITY THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Drug Response Predictor® (DRP) DEVICE Preclinical Ovarian Cancer ClinicalTrials.gov
    2X-121 and dovitinib DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Ixabepilone Injection DRUG Phase PHASE2 Metastatic Breast Cancer ClinicalTrials.gov
    2X-121 DRUG Phase PHASE2 Advanced Ovarian Cancer ClinicalTrials.gov
    Irofulven DRUG Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer Patients ClinicalTrials.gov
    PARP inhibitor 2X-121 DRUG Phase PHASE2 Metastatic Breast Cancer ClinicalTrials.gov
    APO010 DRUG Phase PHASE1 Relapsed/Refractory Multiple Myeloma ClinicalTrials.gov
    LiPlaCis DRUG Phase PHASE1 Phase 1: Advanced or Refractory Solid Tumours ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ALLARITY THERAPEUTICS, INC.
    • Ticker Symbol: ALLR

Search

News categories